News

Under the terms of agreement, Transgenomic will develop the test in the company’s CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of

Prevnar 13 is indicated for active immunization of children 6 weeks through 5 years of age for the prevention of invasive disease caused by 13 Streptococcus pneumoniae (S

As per the terms of the agreement, China Aoxing is expected to fund the development of MoxDuoIV for the China market in exchange for exclusive marketing rights in

Intus Healthcare has reached an exclusive distribution agreement with HealthLinx in February 2009 for the distribution of OvPlex in the UK and Republic of Ireland (ROI) with an

AutoGenomics has developed the automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with genomic and proteomic markers in the area of genetic

The patent expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-ß precursor protein (APP) and thereby treat

According to industry estimates the US market grew by a meagre 1-2% in 2009, in contrast to the 14-15% growth witnessed in emerging markets in Latin America, Asia,

According to Journal of Controlled Release, Dr Simon Richardson and his colleagues provided direct evidence that nanomedicines can be delivered to chosen organelles and manipulated to carry beneficial

The double-blind, placebo-controlled, dose-escalation H5N1 Phase 1 trials were conducted in approximately 100 healthy volunteers age 18 to 45 at three US clinical sites. The trials were designed